Evidence map›Paper›PMID 27711108›Full record

ArticlePLoS neglected tropical diseases2016

Mechanistic Insight into the Host Transcription Inhibition Function of Rift Valley Fever Virus NSs and Its Importance in Virulence.

Kaori Terasaki, Sydney I Ramirez, Shinji Makino

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Live-cell 3D-SIM of Rift Valley fever virus NSs filaments reveals a polygon web architecture.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Review
  5. Dicer-2 mutations inThe Journal of general virology · 2024
    Article
  6. Review
  7. Article
  8. Laboratory Animal Models for Rift Valley Fever Virus Disease.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. A Look intoViruses · 2021
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kaori TerasakiDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Sydney I RamirezDepartment of Pathology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
Shinji MakinoDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
The University of Texas Medical Branch at Galveston · US

Funding

Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Development of Safer,Live Attenuated Rift Valley Fever VaccinesR21AI117445 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MAKINO, SHINJI · 2015 to 2016
$426k
Development of a Novel Rift Valley Fever Virus VaccineR21AI101772 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MAKINO, SHINJI · 2013 to 2014
$425k
NIAID NIH HHS R21 AI101772NIAID NIH HHS R21 AI117445NIAID NIH HHS T32 AI060549
6 · The paper itself

Abstract

Rift Valley fever virus (RVFV), a member of the genus Phlebovirus within the family Bunyaviridae, causes periodic outbreaks in livestocks and humans in countries of the African continent and Middle East. RVFV NSs protein, a nonstructural protein, is a major virulence factor that exhibits several important biological properties. These include suppression of general transcription, inhibition of IFN-β promoter induction and degradation of double-stranded RNA-dependent protein kinase R. Although each of these biological functions of NSs are considered important for countering the antiviral response in the host, the individual contributions of these functions towards RVFV virulence remains unclear. To examine this, we generated two RVFV MP-12 strain-derived mutant viruses. Each carried mutations in NSs that specifically targeted its general transcription inhibition function without affecting its ability to degrade PKR and inhibit IFN-β promoter induction, through its interaction with Sin3-associated protein 30, a part of the repressor complex at the IFN-β promoter. Using these mutant viruses, we have dissected the transcription inhibition function of NSs and examined its importance in RVFV virulence. Both NSs mutant viruses exhibited a differentially impaired ability to inhibit host transcription when compared with MP-12. It has been reported that NSs suppresses general transcription by interfering with the formation of the transcription factor IIH complex, through the degradation of the p62 subunit and sequestration of the p44 subunit. Our study results lead us to suggest that the ability of NSs to induce p62 degradation is the major contributor to its general transcription inhibition property, whereas its interaction with p44 may not play a significant role in this function. Importantly, RVFV MP-12-NSs mutant viruses with an impaired general transcription inhibition function showed a reduced cytotoxicity in cell culture and attenuated virulence in young mice, compared with its parental virus MP-12, highlighting the contribution of NSs-mediated general transcription inhibition towards RVFV virulence.

Indexed as

Transcription, GeneticAnimalsChlorocebus aethiopsHost-Pathogen InteractionsHumansInterferon-betaMiceMutationPromoter Regions, GeneticRift Valley FeverRift Valley fever virusTranscription FactorsVero CellsViral Nonstructural ProteinsVirulence FactorsInterferon-betaTranscription FactorsViral Nonstructural ProteinsVirulence Factors

Identifiers

PMID27711108
PMCPMC5053439
OpenAlexW2528025366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.